Enrico Petrillo MD

Dr. Petrillo is an international leader in healthcare innovation in life sciences and IT with decades of experience as a venture capitalist, strategy consultant, academic physician, founder, and national policy advisor. He leads international research programs for Harvard's flagship teaching hospital, Brigham and Women’s Hospital (BWH) as advisor to the Chair of Medicine and Physician-in-Chief, with Mass. General Hospital is the world’s largest hospital-based research enterprise. He is a Lecturer on the Harvard Medical School faculty and Lead Investigator in Medicine. He is the Executive Director and Co-Founder with the scientific founders of the Network Medicine field of the Network Medicine Alliance consisting of leading Global Universities and Institutes. He is co-founder and co-director of the BWH alliance with Karolinska University Hospital and on the Karolinska Institutet, Sweden faculty. He co-founded two institutional venture capital firms in healthcare technology CB Health and Excel each with multiple funds under management, totaling hundreds of millions of dollars. Dr. Petrillo served on the board of directors for his direct investments, many of which are world leaders in their industries with tens of billions of dollars of value creation, and immeasurable human benefit. Including global leading platforms in Healthcare IT, cancer diagnostics screening, precision cancer therapeutics, health well-being, transplantation, Life Science tools, women's health. Exact Sciences EXAS, TransMedics TMDX, Aileron ALRN, ClearData, Shapeup Virgin Pulse, Biotrove ThermoFisher, Biocius Agilent, Medventive McKesson, Morphotek Eisai, Cytyc Hologic, GeneOhm Sciences BD, EbenX SHPS. He was the founding partner of the technology commercialization group of strategy consulting firm FletcherSpaght Inc, (FSI), a Boston Consulting Group spinout, specializing in advising on Innovation. His clients included Fortune 500, global research institutions, private equity, and venture capital firms. During his tenure at FSI, He led the initiation of world-leading innovation centers for Harvard teaching hospitals BWH and Boston Children’s Hospital. He consummated multiple high-profile technology transfer transactions Including the commercialization of the world’s first cancer portfolio of angiogenesis therapies leading to Celgene being acquired by Bristol M Squibb. This breakthrough has spawned an entire leading field of cancer treatments worldwide. He serves as a national policy advisor to US presidential candidates, senate members, and governmental agencies.